0727 GMT - The market is pricing in tariff risks for pharma stocks despite drugs currently being exempt from U.S. President Trump's potential tariffs, Berenberg analysts say in a note. Uncertainty from tariffs and substantial layoffs at the Food and Drug Administration and other U.S. health departments have dragged pharma share prices lower, they say. Berenberg reiterate its buy ratings on U.K. drugmaker AstraZeneca and French pharma giant Sanofi due to share-price erosion and lower exposure to the U.S. market. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 08, 2025 03:27 ET (07:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.